Reduction of alcohol consumption in chronic alcoholism? Results of new phase III studies with the opioid modulator nalmefene;Trinkmengenreduktion bei Alkoholabhängigen? Ergebnisse neuer phase-iii-studien mit dem opioidrezeptor-modulator nalmefen

Psychopharmakotherapie

Volumn 20, Issue 5, 2013, Pages 220-224

  Mann, Karl ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Alcoholism; Nalmefene; Pharmacotherapy

Indexed keywords

NALMEFENE;

ALCOHOL CONSUMPTION; ALCOHOLISM; DIZZINESS; DRINKING BEHAVIOR; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EUROPEAN UNION; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84884966316     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17. (Pubitemid 44794003)
2. Bart G, Schluger JH, Borg L, Ho A, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005;30:2254-62. (Pubitemid 41643977)
3. Fleming MF, Balousek SL, Grossberg PM, Mundt MP, et al. Brief physician advice for heavy drinking college students: a randomized controlled trial in college health clinics. J Stud Alcohol Drugs 2010;71:23-31.
4. Gual A, He Y, Torup L, van den Brink W, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, asneeded use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013. [Epub ahead of print],
5. Karhuvaara S, Simojoki K, Virta A, Rosberg M, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007;31:1179-87. (Pubitemid 46934385)
6. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ 2004;82:858-66. (Pubitemid 39573744)
7. Lim SS, Vos T, Flaxman AD, Danaei G, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60.
8. Malcolm R, Myrick H, Roberts J, Wang W, etal. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002;17:349-55. (Pubitemid 34626103)
9. Mann K, Bladstrom A, Torup L, Gual A, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013;73:706-13.
10. Mann K, Lemenager T, Hoffmann S, Reinhard I, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2012; doi: 10.1111/adb.12012 [Epub ahead of print],
11. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994;18:1162-7. (Pubitemid 24345524)
12. Mason BJ, Salvato FR, Williams LD, Ritvo EC, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56:719-24. (Pubitemid 29357733)
13. Rosenberg H, Melville J, Levell D, Hodge JE. A 10-year follow-up survey of acceptability of controlled drinking in Britain. J Stud Alcohol 1992;53:441-6.
14. Salize HJ, Jacke C, Kief S, Franz M, et al. Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction 2013;108:62-70.
15. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported ethanol consumption. In: Litten RZ, Allen JP (Hrsg.). Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, New Jersey: Humana Press; 1992:41-72.
16. Soyka M, Rosner S. Nalmefene for treatment of alcohol dependence. Expert Opin Invest Drugs 2010;19:1451-9.
17. Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006;12:80-9. (Pubitemid 44284090)
18. van den Brink W, Sorensen P, Torup L, Mann K, et al. Long-term efficacy, tolerability, and safety of nalmefene as-needed in alcohol-dependence: A randomised, double-blind, placebo-controlled study. 35th Annual RSA Scientific Meeting; San Francisco, California, USA, 2012.
19. Wienberg G. Systems of care for persons with alcohol problems in Germany - an analysis from a public health perspective. In: Mann K (Hrsg.). Neue Therapieansätze bei Alkohol-problemen. Lengerich: Pabst, 2002:17-46.